Literature DB >> 26768031

Markers of metastatic carcinoma of breast origin.

Allen M Gown1, Regan S Fulton1, Patricia L Kandalaft2.   

Abstract

This review summarizes the three major breast-associated markers that can be of assistance in evaluating metastatic carcinomas for which a breast primary diagnosis is entertained. These markers include gross cystic disease fluid protein-15 (GCDFP-15), mammaglobin, and GATA3. The first two are cytoplasmic markers that show comparable sensitivities for breast cancer, although relatively few of the published studies have employed the same antibodies against the target molecule, making direct comparisons challenging. GATA3 is a nuclear transcription factor that shows superior sensitivity to GCDFP-15 and mammaglobin. However, the specificity of GATA3 can pose challenges, inasmuch as carcinomas of the bladder and other sites can show significant levels of positivity. Determination of the optimal panel of antibodies employed in a given clinical setting will thus depend on the non-breast tumours included in the differential diagnosis.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  GATA3; breast; gross cystic disease fluid protein-15; immunohistochemistry; mammaglobin

Mesh:

Substances:

Year:  2016        PMID: 26768031     DOI: 10.1111/his.12877

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  11 in total

Review 1.  Liver metastases.

Authors:  Diamantis I Tsilimigras; Pnina Brodt; Pierre-Alain Clavien; Ruth J Muschel; Michael I D'Angelica; Itaru Endo; Rowan W Parks; Majella Doyle; Eduardo de Santibañes; Timothy M Pawlik
Journal:  Nat Rev Dis Primers       Date:  2021-04-15       Impact factor: 52.329

2.  Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.

Authors:  Kiyong Na; Jung-Yun Lee; Ji-Youn Sung; Gun Min Kim; Ja Seung Koo; Hyun-Soo Kim
Journal:  Virchows Arch       Date:  2018-06-20       Impact factor: 4.064

3.  Metastases to the Breast from Extramammary Nonhematological Malignancies: Case Series.

Authors:  Xue Wan; Heqing Zhang; Yahan Zhang; Yulan Peng
Journal:  Int J Gen Med       Date:  2020-11-12

Review 4.  Metastatic non-small cell lung carcinoma a mimic of primary breast carcinoma-case series and literature review.

Authors:  Rola H Ali; Catalin Taraboanta; Tareq Mohammad; Malcolm M Hayes; Diana N Ionescu
Journal:  Virchows Arch       Date:  2017-11-05       Impact factor: 4.064

5.  Disseminated Carcinomatosis of the Bone Marrow from Occult Breast Cancer Responding to a Sequence of Endocrine Therapy.

Authors:  Takeshi Yamaguchi; Mariko Masumoto; Urara Sakurai; Minoru Nakane
Journal:  Case Rep Oncol       Date:  2020-02-24

6.  Gastric metastasis from invasive lobular breast cancer, mimicking primary gastric cancer: A case report.

Authors:  Dae Hoon Kim; Seung-Myoung Son; Young Jin Choi
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

7.  Suppression of OSCC malignancy by oral glands derived-PIP identified by iTRAQ combined with 2D LC-MS/MS.

Authors:  Qibo Wang; Yuan Zhi; Wenhao Ren; Shaoming Li; Zhichao Dou; Xiaoming Xing; Xinyu Quan; Yuting Wang; Chunmiao Jiang; Xiao Liang; Ling Gao; Keqian Zhi
Journal:  J Cell Physiol       Date:  2019-01-28       Impact factor: 6.384

8.  Inflammatory Breast Cancer from Metastatic Ovarian Cancer.

Authors:  Vuthinun Achariyapota; Tuenjai Chuangsuwanich; Mongkol Benjapibal
Journal:  Case Rep Obstet Gynecol       Date:  2016-03-07

9.  Diffuse Bone Marrow Metastasis as the Initial Presentation of an Occult Breast Cancer.

Authors:  Frank S Fan; Chung-Fan Yang; Yi-Fen Wang
Journal:  Case Rep Oncol Med       Date:  2018-07-22

10.  Metastatic serous borderline tumor with micro-invasive ovarian carcinoma presenting as a breast lump: A case report.

Authors:  Fengge Dong; Xiao Xie; Xue Wei; Miao-Miao Jiao; Junwu Duan; Linlin Pan; Lirong Bi; Zhimin Fan; Ming Yang
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.